EV / EBITDA společnosti ProMIS Neurosciences
Jaká je hodnota metriky EV / EBITDA společnosti ProMIS Neurosciences?
Hodnota metriky EV / EBITDA společnosti ProMIS Neurosciences, Inc. je N/A
Jaká je definice metriky EV / EBITDA?
EV/EBITDA je podniková hodnota dělená EBITDA (zisk před odečtením úroků, daní, odpisů a amortizací). Měří nákladnost akcie a používá se k porovnání společností mezi sebou častěji než P/E ratio. Měří cenu, jakou investor zaplatí za pohyb hotovosti ve společnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA společností v sektoru Health Care sektor na TSX ve srovnání se společností ProMIS Neurosciences
Čemu se věnuje společnost ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Firmy s metrikou ev / ebitda podobnou společnosti ProMIS Neurosciences
- Hodnota metriky EV / EBITDA společnosti Cashrewards je N/A
- Hodnota metriky EV / EBITDA společnosti Cosmo Lady (China) je N/A
- Hodnota metriky EV / EBITDA společnosti Moiselle International je N/A
- Hodnota metriky EV / EBITDA společnosti Atacama Copper je N/A
- Hodnota metriky EV / EBITDA společnosti Stellar AfricaGold je N/A
- Hodnota metriky EV / EBITDA společnosti XpresSpa Inc je N/A
- Hodnota metriky EV / EBITDA společnosti ProMIS Neurosciences je N/A
- Hodnota metriky EV / EBITDA společnosti Genetic Technologies je N/A
- Hodnota metriky EV / EBITDA společnosti Mammoth Services Inc je N/A
- Hodnota metriky EV / EBITDA společnosti Rua Life Sciences Plc je N/A
- Hodnota metriky EV / EBITDA společnosti Europlasma S.A je N/A
- Hodnota metriky EV / EBITDA společnosti Voleo Trading Systems Inc je N/A
- Hodnota metriky EV / EBITDA společnosti Tuktu Resources Ltd je N/A